Navigation Links
Sunesis Reports Financial Results for the Second Quarter 2009
Date:7/29/2009

pse and primary refractory patients are currently being enrolled in Phase 2.
  • Updated clinical data from the Phase 2 study of single agent voreloxin in women with platinum-resistant ovarian cancer were also presented at the ASCO 2009 Annual Meeting. Approximately a third of the study patients have also failed prior treatment with Doxil(R). Three dose cohorts of voreloxin have been studied, 48 mg/m2 given every three weeks, 60 mg/m2 given every four weeks and 75 mg/m2 given every four weeks. Across all three dosing cohorts, 74 patients (52%) experienced disease control, defined as an objective response or stable disease for 12 weeks or more. The preliminary median progression free survival (PFS) for each of the three cohorts by increasing dose is 82 days, 84 days, and 109 days, respectively. The preliminary median PFS for the 44 women who were both platinum resistant and also had failed treatment with Doxil(R) is 90 days.
  • In July, Sunesis received a $1.5 million milestone payment from Biogen Idec (Nasdaq: BIIB) for the selection of a Raf kinase inhibitor development candidate for the treatment of cancer. Biogen Idec is currently conducting IND-enabling GLP preclinical work. Sunesis retains an option to participate in the co-development and co-promotion of the Raf kinase inhibitor resulting from this collaboration.
  • On July 24, 2009, Sunesis applied to transfer the listing of its common stock from The NASDAQ Global Market to The NASDAQ Capital Market. The NASDAQ Capital Market is a continuous trading market that operates in the same manner as The NASDAQ Global Market. All companies listed on The NASDAQ Capital Market must meet certain financial requirements and adhere to NASDAQ's corporate governance standards. Sunesis believes it is in compliance with the minimum stockholders' equity requirement and all
    '/>"/>

  • SOURCE Sunesis Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
    2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
    4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
    5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
    6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
    7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
    8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
    9. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
    10. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
    11. Sunesis to Present at Upcoming Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/31/2015)... ... August 31, 2015 , ... The Global Supply ... risk management and resiliency practitioners with luminaries and thought leaders to advance the ... recognized for their innovations and performance excellence. At that time its principle sponsor, ...
    (Date:8/31/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/v7fdpx/argentina ) ... Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Biomedical Sensors market is estimated at $0.17 billion by ... 2014-2020 The near future will bring Biomedical ... each individual. These sensors can be set to trigger ...
    (Date:8/31/2015)... 2015  For people with Down syndrome, news from ... biotechnology company, located in the Science + Technology Park ... potential therapies yet for people with Down syndrome and other ... Down syndrome and Edwards syndrome aneuploidies in human cell ... . Elixirgen plans to develop this technology into a ...
    (Date:8/31/2015)... HAYWARD, Calif. and SHANGHAI ... Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, ... Phase 2 clinical study for its lead drug ... designed to treat drug-resistant bacteria such as MRSA ... safer and better tolerated therapeutic option than currently ...
    Breaking Biology Technology:Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 2Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 3Argentina Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts 2014-2020 2New Down syndrome therapy discovered 2MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2
    ... Infrastructure &,Construction Private Ltd(OICPL), a wholly owned subsidiary of ... construction of Allopathic Medical,College and Associated Hospital at Saharanpur, ... of the project is Rs250 crores,approx., The project ... total built up area,of 15.66 lac sq ft. It ...
    ... Aug. 21 /Xinhua-PRNewswire-FirstCall/ --,China-Biotics, Inc. (OTC ... leading Chinese firm specializing in the ... probiotics products,today announced it signed a ... Ltd. ("Square Pharmaceutical") to supply probiotics ...
    ... increased 29% and adjusted EPS* of $0.35 ... increased 218% -, - Total Fiscal Year Revenues of $79.8M increased ... $0.99 ... today reported the results for its fourth quarter and fiscal,year ended June 30, 2008., ...
    Cached Biology Technology:Omaxe Infrastructure & Construction Private Ltd Receives LoI for Construction of Allopathic Medical College and Associated Hospital at Saharanpur, UP With Construction Value of Approx 250 Crores 2China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base 2China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base 3Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 2Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 3Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 4Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 5Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 6Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 8Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 9Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 10Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 11Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 12Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 13Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 14Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 15Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 16Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 17Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 18Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 19Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 20Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 21
    (Date:8/20/2015)... Calif. , Aug. 20, 2015   ... focused on improving the user experience and security ... vision technologies, today announced that its TrulySecure™ ... biometric authentication software to be FIDO Certified™. ... TrulySecure for compliance with the FIDO UAF (Universal ...
    (Date:8/18/2015)... , Aug. 18, 2015  Navitas today ... contributor to the Submission Content Management webinar ... a non-profit forum. Dedicated to the Implementation of ... neutral platform for industry, vendors, health authorities, ... and work towards a standard method of ...
    (Date:8/12/2015)... Minn. , Aug. 12, 2015   MedNet ... supports the entire spectrum of clinical research, is proud ... , the company,s comprehensive SaaS-based eClinical technology platform, has ... during the first two quarters of 2015.   Q2 ... second largest quarters measured by contract value sold in ...
    Breaking Biology News(10 mins):TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3MedNet Solutions Experiences Explosive Corporate Growth 2
    ... of us cringe at the sound of the words "parasitic ... actually good for us. , At Michigan State University, researcher ... investigating the role that parasites can play in treating inflammatory ... part of a more than $10 million National Institutes of ...
    ... A faster magnetic resonance imaging (MRI) data-acquisition technique will ... magnetic resonance scanner, yet deliver more precise 3-D images ... Wisconsin-Madison, the faster technique will enable clinics to image ... adults with osteoarthritis-related knee problems - and can help ...
    ... "dead zone" has formed off the Oregon Coast for the ... State University. , A fundamental new trend in atmospheric and ... begun, scientists say, and apparently is expanding its scope beyond ... effect of the low-oxygen zone is also being seen in ...
    Cached Biology News:Parasitic worms used to fight bowel disease 2New MRI technique quickly builds 3-D images of knees 2Marine 'dead zone' off Oregon is spreading 2Marine 'dead zone' off Oregon is spreading 3
    ... Fingerprinting II ... is an optional ... principal component analysis, ... analysis and MANOVA, ...
    Fingerprinting II Informatix optional matrix types module, is an optional module that adds external similarity and distance matrix functions to the Fingerprinting II Informatix software package....
    ... cycler is a completely redesigned and updated ... it accepts the full line of well-proven ... precision in thermal performance as the DNA ... allowing easy transport of protocols among platforms. ...
    ... hand-held applications or for use in an ... hand-held eight-port disposable manifold provides greater ease, ... pipette. The StatMatic II can be connected ... can completely fill a microplate with one-handed ...
    Biology Products: